Archive ready
第87期事業報告書
https://www.jintan.co.jp/corp/ir/uploads/ba81b1be7b38dc55c4acf0141dfe372afdf97109.pdfJuly 1, 2026 at 04:55 PM JST•The archive page, viewer, and downloads use this saved version.
July 1, 2026 at 04:55 PM JST·www.jintan.co.jp
The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
Saved PDF
第87期事業報告書
StartedJuly 1, 2026 at 04:55 PM JST
File size1.47 MB
SHA-256d05bb50e3c0ce4ed51a4be66b3785230015149a3adfcb3435971c3f150e438ce
About this pageAI generated
This document reports on the business overview of our group for the period from April 1, 2023, to March 31, 2024. The Japanese economy is gradually recovering, but consumer spending remains weak due to rising prices. Our healthcare business shows signs of recovery, particularly with products like 'Bifina®', achieving a sales increase of 9.2% year-on-year to 12,406 million yen, and an operating profit increase of 25.8% to 716 million yen. The capsule contract business is also performing well, and we aim for growth through new technology development and rebranding efforts.